VCAM1 and Hyperglycemia: Notably, our study showed no significant difference in fasting blood glucose (FBG) levels after treatment, which could indicate that hyperglycemia-induced oxidative stress or insulin resistance might be driving the increased VCAM-1 expression, independently of clinical improvements.